Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘ASGCT CAR T cells’

Engineering Immunity – what did we learn from ASGCT20?

ASGCT Virtual: We are thoroughly enjoying the “live” annual meeting of the American Society of Gene and Cell Therapy (ASGCT).

Unlike other virtual meetings that have recorded presentations, ASGCT are running a live format, with presenters giving their talks in real-time from wherever in the world they may be. By and large this has worked well, and it definitely felt as though you were at the meeting.

We are also enjoying the ePoster hall, and in particular, the short audio tour that many presenters have made to take you through their poster. Obviously, it’s not a substitute for in-person contact, but who would want to be in a crowded poster hall or meeting room in these uncertain times with the potential for the coronavirus lurking about?

Earlier today we “attended” a virtual ASGCT20 scientific session with oral presentations organized by the American Society for Transplantation and Cellular Therapy (ASTCT) on Engineering Immunity.

Four speakers focused on CAR T cell therapy in non-B cell malignancies – what did we learn?  It turns out the answer was quite a bit!

To find out more about our oncology analysis and get a heads up on insights and commentary emerging from the ASGCT meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

Dr Michel Sadelain AACR 2016

Dr Michel Sadelain at AACR 2016

Dr Michel Sadelain, Director of Cell Engineering at Memorial Sloan Kettering Cancer Center in New York is a pioneer in the field of adoptive cell therapy.

Without his contribution, it is unlikely CAR T cell therapy would be where it is today.

He’s also President of the American Society of Gene and Cell Therapy (ASGCT), whose annual meeting is currently underway in Washington DC from May 4 to 7 (Twitter #ASGCT16).

Recently at the annual meeting of the American Association for Cancer Research (AACR), Dr Sadelain gave an outstanding presentation on turbo-charged CAR T cells, and shared some of his ideas on how to move the field forward.

In New Orleans, he also kindly spoke to BSB, and discussed how he thinks cell therapy researchers may obtain the “holy grail” of getting CAR T cell therapies to work effectively in solid tumors.

Dr Sadelin is someone who wants to break the immunology rules!

Not surprisingly, Dr Sadelain is optimistic and doesn’t share the view expressed by Dr Steven Rosenberg on CAR T cell therapies being limited to mostly hematologic malignancies when we interviewed him a year ago at last year’s ASGCT meeting. There’s nothing like a friendly controversy to spice the field up!

Subscribers can log-in or you can purchase access below to read more about what Dr Sadelain told BSB at AACR…

This content is restricted to subscribers

error: Content is protected !!